INTRODUCTION: Virological responses to interferon (IFN) treatment for chronic hepatitis C (CHC) have been found to be correlated with racial differences. Furthermore, higher sustained virological response (SVR) rates were obtained in many randomised clinical trials (RCT) in Caucasian patients with CHC after treating with peg-IFN than those with IFN. However, it is not clear whether this conclusion can be adapted to patients of Chinese descent. METHODS: A search of MEDLINE and China National Knowledge Infrastructure between 1966 and 2008 was performed. Trials comparing the use of peg-IFN plus ribavirin vs. IFN plus ribavirin in treating Chinese patients with CHC were assessed. RESULTS: Of the 94 studies screened, seven RCTs including 398 patients (peg-IFN therapy 232, IFN therapy 166) were analysed. The SVRs obtained in patients treated with peg-IFN plus ribavirin were significantly higher than in patients treated with IFN plus ribavirin [70% vs. 35%, relative risk, 1.76; 95% confidence interval: 1.21-2.56; p (0.01)]. Withdrawal rates were similar between patients treated with peg-IFN plus ribavirin and IFN plus ribavirin. CONCLUSION: Chinese patients with CHC also have a greater likelihood of achieving an SVR with peg-IFN plus ribavirin.
INTRODUCTION: Virological responses to interferon (IFN) treatment for chronic hepatitis C (CHC) have been found to be correlated with racial differences. Furthermore, higher sustained virological response (SVR) rates were obtained in many randomised clinical trials (RCT) in Caucasian patients with CHC after treating with peg-IFN than those with IFN. However, it is not clear whether this conclusion can be adapted to patients of Chinese descent. METHODS: A search of MEDLINE and China National Knowledge Infrastructure between 1966 and 2008 was performed. Trials comparing the use of peg-IFN plus ribavirin vs. IFN plus ribavirin in treating Chinese patients with CHC were assessed. RESULTS: Of the 94 studies screened, seven RCTs including 398 patients (peg-IFN therapy 232, IFN therapy 166) were analysed. The SVRs obtained in patients treated with peg-IFN plus ribavirin were significantly higher than in patients treated with IFN plus ribavirin [70% vs. 35%, relative risk, 1.76; 95% confidence interval: 1.21-2.56; p (0.01)]. Withdrawal rates were similar between patients treated with peg-IFN plus ribavirin and IFN plus ribavirin. CONCLUSION: Chinese patients with CHC also have a greater likelihood of achieving an SVR with peg-IFN plus ribavirin.
Authors: D Cheng; E Liu; Y Li; R Liu; L Bai; Y Chen; Y Wang; Y Chu; M Wu; G Cheng; S Zhao Journal: Eur J Clin Microbiol Infect Dis Date: 2014-03 Impact factor: 3.267
Authors: Masao Omata; Tatsuo Kanda; Osamu Yokosuka; Darrell Crawford; Mamun Al-Mahtab; Lai Wei; Alaaeldin Ibrahim; George K K Lau; Barjesh C Sharma; Saeed S Hamid; Wan-Long Chuang; A Kadir Dokmeci Journal: Hepatol Int Date: 2015-05-05 Impact factor: 9.029